The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways

doi:10.1016/j.ceca.2019.02.010

Cell Calcium

Volume 79, May 2019, Pages 80-88

https://doi.org/10.1016/j.ceca.2019.02.010 Get rights and content

Highlights

•
TRPML1 is specifically upregulated in triple-negative breast cancers (TNBCs).
•
Downregulation and pharmacological inhibition suppress the growth of TNBCs.
•
TRPML1 regulates TNBC development through controlling mTORC1 activity and lysosomal ATP release.

Abstract

The triple-negative breast cancer (TNBC) that comprises approximately 10%–20% of breast cancers is an aggressive subtype lacking effective therapeutics. Among various signaling pathways, mTORC1 and purinergic signals have emerged as potentially fruitful targets for clinical therapy of TNBC. Unfortunately, drugs targeting these signaling pathways do not successfully inhibit the progression of TNBC, partially due to the fact that these signaling pathways are essential for the function of all types of cells. In this study, we report that TRPML1 is specifically upregulated in TNBCs and that its genetic downregulation and pharmacological inhibition suppress the growth of TNBC. Mechanistically, we demonstrate that TRPML1 regulates TNBC development, at least partially, through controlling mTORC1 activity and the release of lysosomal ATP. Because TRPML1 is specifically activated by cellular stresses found in tumor microenvironments, antagonists of TRPML1 could represent anticancer drugs with enhanced specificity and potency. Our findings are expected to have a major impact on drug targeting of TNBCs.

Graphical abstract

Introduction

Breast cancer is a very common and fatal cancer in women. It is a heterogeneous disease classified into three major subtypes. Two of these are defined by the expression of steroid hormone receptors (estrogen receptor [ER] and progesterone receptor [PR]) and overexpression and/or amplification of the receptor tyrosine kinase HER2 (also known as ERBB2). Agents targeting these proteins have led to a significant increase in patient survival [[1], [2], [3], [4], [5]]. In contrast, the most aggressive and metastatic form of breast cancer is the triple-negative breast cancer (TNBC) subtype, which is defined by the lack of expression of ER, PR and HER2 and its resistance to common therapies targeting these molecules [[1], [2], [3], [4], [5]]. TNBC represents approximately 10%–20% of breast cancers [6,7]. The major cause of TNBC mortality is the propensity of TNBC cells to metastasize to nearby normal tissues and organs and even spread to distant parts of the body through the blood or lymph system. Therefore, understanding the basic cellular and molecular mechanisms of TNBC development is crucial for devising new therapies for this disease.

The mammalian target of rapamycin complex 1 (mTORC1) is crucial for autophagy induction in response to nutrient shortage and cellular stress. Continuous loss of mTORC1 activity during nutrient and energy deprivation leads to cell death [8,9] because mTORC1 is also required for protein synthesis, metabolism, cell growth and proliferation and cellular homeostasis [[10], [11], [12]]. Mounting evidence suggests that mTORC1 represents a major signaling pathway responsible for cancer cell growth and survival [13,14]. Hyperactivation of mTORC1 pathway is common in human cancer including breast cancer [12,14,15]. In particular, activated mTORC1 is more frequently observed in TNBC (36%) than in other subtypes of breast cancer, rendering mTORC1 a potential target for TNBC therapy [[16], [17], [18]]. As such, several molecules that inhibit mTORC1 are currently in clinical trials for the treatment of multiple cancer types, including breast cancer [17,[19], [20], [21], [22], [23]].

Adenosine triphosphate (ATP) is actively released to the extracellular environment in response to tissue damage and cellular stress [24]. Increased levels of extracellular ATP at tumor sites have been suggested to play a key role in host-tumor interaction [[24], [25], [26]], likely acting on their specific cell surface receptors to increase motility, invasion and metastasis of many cancers [[27], [28], [29], [30]], including breast cancer [31,32]. Interestingly, the lysosome plays an important role in mTORC1 signaling and is a major source of ATP. Specifically, mTORC1 is recruited to the surface of the lysosome to be activated by nutrients within the lysosome [33]. Lysosomal ATP (˜ 1 mM) [34,35] can be released into extracellular space via lysosomal exocytosis [[35], [36], [37]], thereby regulating cancer migration and invasion [36,38]. Thus, lysosomes may regulate cancer development by controlling both mTORC1 and ATP signaling pathways.

Recently, we [39], and others [40,41], demonstrated that Transient Receptor Potential Mucolipin 1 (TRPML1 or ML1), the lysosomal Ca²⁺ release channel, is required for sustained activity of mTORC1 under nutrient stress but not under normal conditions. This regulation of mTORC1 by ML1 is essential for cells to survive extreme conditions [39]. Mounting evidence also suggests that ML1 is a key regulator of lysosomal exocytosis [[42], [43], [44]]. Here we show that ML1 supports tumor development by promoting both mTORC1 activity and lysosomal ATP release. We show that ML1 is markedly upregulated in highly metastatic TNBC when compared with non-metastatic ER⁺/PR⁺ MCF-7 breast cancer cell, as well as the non-tumorigenic MCF-10 A epithelial cell line. The mRNA of ML1 from TNBC patients is also significantly higher than that from ER⁺/PR⁺ breast cancer patients. Molecular abrogation or pharmacological inhibition of ML1 suppresses TNBC cell proliferation and invasion in vitro, and tumor growth and progression in vivo. In addition, we demonstrate that ML1 regulates TNBC growth by promoting mTORC1 activity and facilitating TNBC invasion through increasing lysosomal ATP release. Our work suggests that inhibiting ML1 could be a potential therapeutic strategy for TNBC.

Section snippets

Cell culture

MCF10 A breast normal cells were grown in DMEM/F12 (1:1). Human breast cancer cell lines MDA-MB-231, MCF7, and Hs 578 T were grown in DMEM, while SUM159PT were cultured using F12 medium (Life Technologies, Carlsbad, CA) supplemented with 10% FBS (Life Technologies). All cultures were maintained at 37 °C in a 5% CO₂ incubator.

Antibodies, plasmids and reagents

The following primary antibodies were used for western blotting and immunofluorescence staining: anti-p-p70S6K (T389) (9206, Cell Signaling Technology), anti-p70S6K (Cell

ML1 is highly expressed in metastatic breast cancer cells and breast tumors

We first investigated the expression profile of ML1 in non-tumorigenic MCF-10 A cells and several breast cancer cell lines, including the non-metastatic ER⁺/PR⁺ breast cancer cell line MCF-7 and three metastatic TNBC cell lines MDA-MB-231, Hs 578 T and SUM159PT [50,51]. ML1 expression levels were gauged by quantitative PCR with reverse transcription (RT-PCR). ML1 mRNA was found to be specifically upregulated in aggressive, metastatic TNBC cell lines including MDA-MB-231, Hs 578 T and SUM159PT

Discussion

Although TNBC is the most aggresive malignant cancercausing high mortality rates among women, therapeutic options for this disease remain limited. This is partially due to the lack of our understanding of key pathways associated with TNBCs. In this study, we report that ML1 is specifically elevated in TNBC cell lines and patients and is associated with increased mTORC1 activity and lysosomal ATP release into the extracellular space to promote TNBC growth and invasion.

In agreement with previous

Conflicts of interest statement

The authors declare that there is no conflict of interest.

Acknowledgements

This work was supported by DMRF Equipment Grant, CIHR grant (PJT-156102), and CFI Leaders Opportunity Fund-Funding for research infrastructure (29291). We thank Mitsunori Fukuda for the Syt-VII-DN plasmid and Haoxing Xu for his constant support. We appreciate the encouragement and helpful comments from other members of the Dong laboratory and El Hiani laboratories.

References (91)

Y. Wang et al.
CDK7-dependent transcriptional addiction in triple-negative breast cancer
Cell
(2015)
L.M. Ooms et al.
The inositol polyphosphate 5-phosphatase PIPP regulates AKT1-dependent breast cancer growth and metastasis
Cancer Cell
(2015)
A. Britschgi et al.
JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer
Cancer Cell
(2012)
R.A. Saxton et al.
mTOR signaling in growth, metabolism, and disease
Cell
(2017)
L. Bar-Peled et al.
Regulation of mTORC1 by amino acids
Trends Cell Biol.
(2014)
M. Laplante et al.
mTOR signaling in growth control and disease
Cell
(2012)
S. Walsh et al.
mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors
Breast
(2012)
Y. Chen et al.
Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced autophagy and Akt signaling
J. Biol. Chem.
(2014)
Y. Zhang et al.
Extracellular ATP enhances in vitro invasion of prostate cancer cells by activating Rho GTPase and upregulating MMPs expression
Cancer Lett.
(2010)
K. Shi et al.
Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner
J. Thromb. Haemost.
(2013)

D. Schumacher et al.

Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor

Cancer Cell

(2013)

Q. Cao et al.

Dong XP: SLC17A9 protein functions as a lysosomal ATP transporter and regulates cell viability

J. Biol. Chem.

(2014)

C.O. Wong et al.

Drosophila TRPML is required for TORC1 activation

Curr. Biol.

(2012)

Q. Cao et al.

BK channels alleviate lysosomal storage diseases by providing positive feedback regulation of lysosomal Ca2+ release

Dev. Cell

(2015)

M. Samie et al.

A TRP channel in the lysosome regulates large particle phagocytosis via focal exocytosis

Dev. Cell

(2013)

M.A. Samie et al.

Lysosomal exocytosis and lipid storage disorders

J. Lipid Res.

(2014)

Y. Sancak et al.

Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids

Cell

(2010)

M. Vilella-Bach et al.

The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression

J. Biol. Chem.

(1999)

Y. Miao et al.

A TRP channel senses lysosome neutralization by pathogens to trigger their expulsion

Cell

(2015)

D. Hoshino et al.

Exosome secretion is enhanced by invadopodia and drives invasive behavior

Cell Rep.

(2013)

P. Marcato et al.

Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling

Mol. Oncol.

(2015)

G.P. Gupta et al.

Cancer metastasis: building a framework

Cell

(2006)

M.N. Sharifi et al.

Autophagy promotes focal adhesion disassembly and cell motility of metastatic tumor cells through the direct interaction of Paxillin with LC3

Cell Rep.

(2016)

H. Maes et al.

Tumor vessel normalization by chloroquine independent of autophagy

Cancer Cell

(2014)

A.K. Murugan et al.

Mutations in critical domains confer the human mTOR gene strong tumorigenicity

J. Biol. Chem.

(2013)

B. Levine et al.

Autophagy in the pathogenesis of disease

Cell

(2008)

C. Cang et al.

Ren D: mTOR regulates lysosomal ATP-sensitive two-pore Na(+) channels to adapt to metabolic state

Cell

(2013)

Y. Zhang et al.

BRMS1 sensitizes breast Cancer cells to ATP-Induced growth suppression

Biores. Open Access

(2013)

C. Arsenis et al.

Degradation of nucleic acids by lysosomal extracts of rat liver and Ehrlich ascites tumor cells

J. Biol. Chem.

(1970)

L. Ma et al.

Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

Nature

(2007)

L. Lin et al.

CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer

Oncotarget

(2015)

C. Yam et al.

Targeting the molecular subtypes of triple negative breast cancer: understanding the diversity to progress the field

Oncologist

(2017)

L.A. Carey et al.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

Clin. Cancer Res.

(2007)

M.C. Maiuri et al.

Self-eating and self-killing: crosstalk between autophagy and apoptosis

Nat. Rev. Mol. Cell Biol.

(2007)

Y. Liu et al.

Autosis and autophagic cell death: the dark side of autophagy

Cell Death Differ.

(2015)

A.C. Hsieh et al.

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Nature

(2012)

S.A. Wander et al.

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy

Breast Cancer Res. Treat.

(2013)

M. Cargnello et al.

The expanding role of mTOR in cancer cell growth and proliferation

Mutagenesis

(2015)

S.H. Ueng et al.

Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas

Int. J. Clin. Exp. Pathol.

(2012)

R. Hatem et al.

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

Oncotarget

(2016)

E. Paplomata et al.

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

Ther. Adv. Med. Oncol.

(2014)

S.A. Wander et al.

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

J. Clin. Invest.

(2011)

B. Marty et al.

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

Breast Cancer Res.

(2008)

R.J. Shaw et al.

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Nature

(2006)

F. Di Virgilio et al.

Extracellular purines, purinergic receptors and tumor growth

Oncogene

(2016)

Cited by (39)

Endolysosomal TRPML1 channel regulates cancer cell migration by altering intracellular trafficking of E-cadherin and β<inf>1</inf>-integrin
2024, Journal of Biological Chemistry
Metastasis still accounts for 90% of all cancer-related death cases. An increase of cellular mobility and invasive traits of cancer cells mark two crucial prerequisites of metastasis. Recent studies highlight the involvement of the endolysosomal cation channel TRPML1 in cell migration. Our results identified a widely antimigratory effect upon loss of TRPML1 function in a panel of cell lines in vitro and reduced dissemination in vivo. As mode-of-action, we established TRPML1 as a crucial regulator of cytosolic calcium levels, actin polymerization, and intracellular trafficking of two promigratory proteins: E-cadherin and β₁-integrin. Interestingly, KO of TRPML1 differentially interferes with the recycling process of E-cadherin and β₁-integrin in a cell line–dependant manner, while resulting in the same phenotype of decreased migratory and adhesive capacities in vitro. Additionally, we observed a coherence between reduction of E-cadherin levels at membrane site and phosphorylation of NF-κB in a β-catenin/p38-mediated manner. As a result, an E-cadherin/NF-κB feedback loop is generated, regulating E-cadherin expression on a transcriptional level. Consequently, our findings highlight the role of TRPML1 as a regulator in migratory processes and suggest the ion channel as a suitable target for the inhibition of migration and invasion.
Relevance of lysosomal Ca<sup>2+</sup> signalling machinery in cancer
2022, Cell Calcium
In comparison with normal cells, cancer cells are equipped with a higher number of lysosomes, involved in degradative and non-degradative roles. In particular, the lysosome is a Ca²⁺signalling hub, and the enhancement of this interconnected machinery in cancer cells has recently prompted investigations into the role that lysosomal ion channels play in oncology. The present review reports findings about the emerging role of lysosomal Ca²⁺channels: Two-Pore Channels (TPCs), Transient Receptor Potential Cation Channels (TRPMLs; mucolipins), and Purinergic X Receptor 4 (P2×4R), in a variety of cancer models, highlighting their impact on crucial functions such as the regulation of autophagy and the composition of the tumour microenvironment, including the secretion-mediated interplay with immune and endothelial cells. Notably, recent evidence indicates that, by regulating tumour secretome, lysosomal Ca²⁺ signalling can affect the composition of the tumour-infiltrating immune cell repertoire. Intriguingly, the data so far available show that the protumoral/antitumoral role of lysosomal Ca²⁺ channels can differ according to the specific genetic context, types of cancer and the malignancy stage, and signals from the microenvironment.
Lysosomal Zn<sup>2+</sup> release triggers rapid, mitochondria-mediated, non-apoptotic cell death in metastatic melanoma
2021, Cell Reports
During tumor progression, lysosome function is often maladaptively upregulated to match the high energy demand required for cancer cell hyper-proliferation and invasion. Here, we report that mucolipin TRP channel 1 (TRPML1), a lysosomal Ca²⁺ and Zn²⁺ release channel that regulates multiple aspects of lysosome function, is dramatically upregulated in metastatic melanoma cells compared with normal cells. TRPML-specific synthetic agonists (ML-SAs) are sufficient to induce rapid (within hours) lysosomal Zn²⁺-dependent necrotic cell death in metastatic melanoma cells while completely sparing normal cells. ML-SA-caused mitochondria swelling and dysfunction lead to cellular ATP depletion. While pharmacological inhibition or genetic silencing of TRPML1 in metastatic melanoma cells prevents such cell death, overexpression of TRPML1 in normal cells confers ML-SA vulnerability. In the melanoma mouse models, ML-SAs exhibit potent in vivo efficacy of suppressing tumor progression. Hence, targeting maladaptively upregulated lysosome machinery can selectively eradicate metastatic tumor cells in vitro and in vivo.
p53 mitigates the effects of oncogenic HRAS in urothelial cells via the repression of MCOLN1
2021, iScience
Citation Excerpt :
As a result, TRPML1 inhibition or MCOLN1 knockdown disrupts ERK activation and cell proliferation in HRAS-driven cancer cells. TRPML1-dependent vesicle exocytosis is also necessary for the release of lysosomal ATP, which in the case of triple-negative breast cancers, stimulates cell migration and metastases (Xu et al., 2019). In other cancers, TRPML1 promotes untrammeled proliferation and tumor growth via mTORC1 (Hu et al., 2019; Xu et al., 2019).
Inhibition of TRPML1, which is encoded by MCOLN1, is known to deter cell proliferation in various malignancies. Here, we report that the tumor suppressor, p53, represses MCOLN1 in the urothelium such that either the constitutive loss or ectopic knockdown of TP53—in both healthy and bladder cancer cells—increased MCOLN1 expression. Conversely, nutlin-mediated activation of p53 led to the repression of MCOLN1. Elevated MCOLN1 expression in p53-deficient cancer cells, though not sufficient for bolstering proliferation, augmented the effects of oncogenic HRAS on proliferation, cytokine production, and invasion. Our data suggest that owing to derepression of MCOLN1, urothelial cells lacking p53 are poised for tumorigenesis driven by oncogenic HRAS. Given our prior findings that HRAS mutations predict addiction to TRPML1, this study points to the utility of TRPML1 inhibitors for mitigating the growth of a subset of urothelial tumors that lack p53.
The role of endolysosomal trafficking in anticancer drug resistance
2021, Drug Resistance Updates
Multidrug resistance (MDR) remains a major obstacle towards curative treatment of cancer. Despite considerable progress in delineating the basis of intrinsic and acquired MDR, the underlying molecular mechanisms remain to be elucidated. Emerging evidences suggest that dysregulation in endolysosomal compartments is involved in mediating MDR through multiple mechanisms, such as alterations in endosomes, lysosomes and autophagosomes, that traffic and biodegrade the molecular cargo through macropinocytosis, autophagy and endocytosis. For example, altered lysosomal pH, in combination with transcription factor EB (TFEB)-mediated lysosomal biogenesis, increases the sequestration of hydrophobic anti-cancer drugs that are weak bases, thereby producing an insufficient and off-target accumulation of anti-cancer drugs in MDR cancer cells. Thus, the use of well-tolerated, alkalinizing compounds that selectively block Vacuolar H⁺-ATPase (V-ATPase) may be an important strategy to overcome MDR in cancer cells and increase chemotherapeutic efficacy. Other mechanisms of endolysosomal-mediated drug resistance include increases in the expression of lysosomal proteases and cathepsins that are involved in mediating carcinogenesis and chemoresistance. Therefore, blocking the trafficking and maturation of lysosomal proteases or direct inhibition of cathepsin activity in the cytosol may represent novel therapeutic modalities to overcome MDR. Furthermore, endolysosomal compartments involved in catabolic pathways, such as macropinocytosis and autophagy, are also shown to be involved in the development of MDR. Here, we review the role of endolysosomal trafficking in MDR development and discuss how targeting endolysosomal pathways could emerge as a new therapeutic strategy to overcome chemoresistance in cancer.
Two-pore and TRPML cation channels: Regulators of phagocytosis, autophagy and lysosomal exocytosis
2021, Pharmacology and Therapeutics
Citation Excerpt :
Increased levels of ATP secretion, which occurs via lysosomal exocytosis, result in increased motility, invasion and metastasis of many cancers (W. H. Li et al., 2013; Schumacher, Strilic, Sivaraj, Wettschureck, & Offermanns, 2013; Shi, Queiroz, Stap, Richel, & Spek, 2013; Y. Zhang et al., 2010). Xu and collaborators showed that, in TNBC, TRPML1 supports tumor growth by promoting mTORC1 activity and lysosomal ATP release by enhancing lysosomal exocytosis (M. Xu et al., 2019). Thus, molecular abrogation or pharmacological inhibition of TRPML1 was shown to suppress TNBC proliferation and invasion in vitro, and tumor growth and progression in vivo (M. Xu et al., 2019).
The old Greek saying “Panta Rhei” (“everything flows”) is true for all life and all living things in general. It also becomes nicely evident when looking closely into cells. There, material from the extracellular space is taken up by endocytic processes and transported to endosomes where it is sorted either for recycling or degradation. Cargo is also packaged for export through exocytosis involving the Golgi network, lysosomes and other organelles. Everything in this system is in constant motion and many proteins are necessary to coordinate transport along the different intracellular pathways to avoid chaos. Among these proteins are ion channels., in particular TRPML channels (mucolipins) and two-pore channels (TPCs) which reside on endosomal and lysosomal membranes to speed up movement between organelles, e.g. by regulating fusion and fission; they help readjust pH and osmolarity changes due to such processes, or they promote exocytosis of export material. Pathophysiologically, these channels are involved in neurodegenerative, metabolic, retinal and infectious diseases, cancer, pigmentation defects, and immune cell function, and thus have been proposed as novel pharmacological targets, e.g. for the treatment of lysosomal storage disorders, Duchenne muscular dystrophy, or different types of cancer. Here, we discuss the similarities but also differences of TPCs and TRPMLs in regulating phagocytosis, autophagy and lysosomal exocytosis, and we address the contradictions and open questions in the field relating to the roles TPCs and TRPMLs play in these different processes.

View all citing articles on Scopus

¹: Equal contribution.

View full text

The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways

Highlights

Abstract

Graphical abstract

Introduction

Section snippets

Cell culture

Antibodies, plasmids and reagents

ML1 is highly expressed in metastatic breast cancer cells and breast tumors

Discussion

Conflicts of interest statement

Acknowledgements

Cell

Cancer Cell

Cancer Cell

Cell

Trends Cell Biol.

Cell

Breast

J. Biol. Chem.

Cancer Lett.

J. Thromb. Haemost.

Cancer Cell

J. Biol. Chem.

Curr. Biol.

Dev. Cell

Dev. Cell

J. Lipid Res.

Cell

J. Biol. Chem.

Cell

Cell Rep.

Mol. Oncol.

Cell

Cell Rep.

Cancer Cell

J. Biol. Chem.

Cell

Cell

Biores. Open Access

J. Biol. Chem.

Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

Nature

CCL18 from tumor-associated macrophages promotes angiogenesis in breast cancer

Oncotarget

Targeting the molecular subtypes of triple negative breast cancer: understanding the diversity to progress the field

Oncologist

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

Clin. Cancer Res.

Self-eating and self-killing: crosstalk between autophagy and apoptosis

Nat. Rev. Mol. Cell Biol.

Autosis and autophagic cell death: the dark side of autophagy

Cell Death Differ.

The translational landscape of mTOR signalling steers cancer initiation and metastasis

Nature

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy

Breast Cancer Res. Treat.

The expanding role of mTOR in cancer cell growth and proliferation

Mutagenesis

Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas

Int. J. Clin. Exp. Pathol.

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

Oncotarget

The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers

Ther. Adv. Med. Oncol.

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

J. Clin. Invest.

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

Breast Cancer Res.

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Nature

Extracellular purines, purinergic receptors and tumor growth

Oncogene